

CORNERSTONES INFLAMMATORY BOWEL DISEASE ROUNDTABLES™ 2017

We are excited to offer a special program for your education in inflammatory bowel disease. Cornerstones Health is a non-profit medical education company founded by gastroenterologists with a mission of delivering original and highly customized education to our colleagues and trainees. Using a unique roundtable format and workbooks instead of didactic slides, our trained expert faculty will facilitate a highly interactive program for you that will provide this information using a curriculum that includes both basic and cutting edge concepts in the diagnosis and management of IBD patients.

This is a competency-based curriculum that has been developed by our faculty to meet the needs of our colleagues and answer some of the most challenging questions. Because of our non-profit status and our multiple sponsors, this program should satisfy the requirements of the most rigorous institutional industry-academic policies.

Whether your training program provides you with a structured and comprehensive curriculum in IBD or has more of a “catch as catch can” approach to IBD education, this program will be invaluable.

We look forward to sharing this exciting program with you.



Marla C. Dubinsky, MD



David T. Rubin, MD

Co-Founders, Cornerstones Health

Facilitated by:

David Rubin, MD
University of Chicago Medicine

November 17th, 2017
3:30pm – 5:30pm

Banner University Medical Ctr

1501 N Campbell Avenue
Conference Rm 6302
Tucson, AZ 85724
(520) 626-3992

For more information about this Roundtable event, please call 323-482-1123 or email info@cornerstoneshealth.org

OBJECTIVES

After attending this Roundtable, clinicians and practitioners should be able to:

- Incorporate advances in therapeutic options for the treatment of IBD, with specific emphasis on biologics and immunomodulators in Crohn's disease and 5-ASA therapies in ulcerative colitis.
- Incorporate emerging therapies and their possible place in the future of IBD management.
- Consider the implications for short and long-term outcomes in IBD based on clinical presentation and treatment strategy.
- Incorporate quality measures to improve patient outcomes.
- Incorporate knowledge of new information on role of dysplasia and cancer screening.
- Understand the complexities of risk benefit discussions and incorporate tools to improve communication.
- Understand the role of the human microbiome in IBD and its potential for future approaches to diagnosis and treatment.

WHO SHOULD ATTEND

This activity is intended for gastroenterologists, gastroenterology fellows, trainees, and allied healthcare professionals with an interest in treating pediatric and adult patients with IBD.

CONTINUING MEDICAL EDUCATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Cornerstones Health. Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits.*™ Physicians should claim only credit commensurate with the extent of their participation in the activity.



SUPPORT

This educational activity is supported by independent medical educational grants from Abbvie, Salix Pharmaceuticals, and Takeda Pharmaceuticals, USA Inc.